CharlesMRudinMDPhD

Hematologic Oncology, Thoracic Cancer

Chief, Thoracic Oncology, Memorial Sloan Kettering Cancer Center

Overview of Dr. Rudin

Dr. Charles Rudin is an oncologist in New York, NY and is Chief of Thoracic Oncology at Memorial Sloan Kettering Cancer Center. He received his medical degree and PhD from University of Chicago Pritzker School of Medicine. He specializes in lung cancer research and clinical care.

Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021
Book by Phone+1(213) 341-7999
Is this information wrong?

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1995 - 1998
University of ChicagoResidency, Internal Medicine, 1993 - 1995
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1993

Certifications & Licensure

FL State Medical License 2022 - Present
NJ State Medical License 2018 - 2025
NY State Medical License 2013 - 2025
MD State Medical License 2003 - 2013
IL State Medical License 1993 - 2005

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2010

Clinical Trials

Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 1, Phase 2
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2001 Apr 01
Completed
Phase 1
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors Start of enrollment: 2001 Mar 01
Completed
Phase 1
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2003 Apr 01
Completed
Phase 1, Phase 2
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery Start of enrollment: 2004 Aug 01
Completed
Phase 2
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2004 Nov 01
Completed
Phase 2
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2007 Apr 01
Completed
Phase 1
Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment Start of enrollment: 2006 Sep 01
Completed
Phase 2
Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 Start of enrollment: 2019 Dec 11
Recruiting
Roles: Contact
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2019 Mar 15
Completed
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions.
Joseph B Hiatt, Anna-Lisa Doebley, Henry U Arnold, Mohamed Adil, Holly Sandborg, Thomas W Persse, Minjeong Ko, Feinan Wu, Alvaro Quintanal Villalonga, Rafael Santana-D...> ;Science Advances. 2024 Apr 12
1 citations
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade inmutant lung cancer.
Ray Pillai, Sarah E LeBoeuf, Yuan Hao, Connie New, Jenna L E Blum, Ali Rashidfarrokhi, Shih Ming Huang, Christian Bahamon, Warren L Wu, Burcu Karadal-Ferrena, Alberto ...> ;Science Advances. 2024 Mar 29
1 citations
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.
Elkrief, A., Waters, N., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N., Lumish, M., Giardina, P., Chaft, J., Eng, J., Motzer, R.,...> ;Cancer Immunology Research. 2024 Mar 4
A Lung Cancer Mouse Model Database.
Ling Cai, Ying Gao, Ting Chen, Monte Winslow, Guanghua Xiao, Trudy Oliver, Yang Xie, Ralph DeBerardinis, Charles Rudin, John Minna> ;Biorxiv. 2024 Feb 29
Functional Characterisation of the ATOH1 Molecular Subtype Indicates a Pro-Metastatic Role in Small Cell Lung Cancer.
Catozzi, A., Peiris-Pagès, M., Humphrey, S., Revill, M., Morgan, D., Roebuck, J., Chen, Y., Davies-Williams, B., Lallo, A., Galvin, M., Pearce, S., Kerr, A., Priest, L...> ;Biorxiv. 2024 Feb 17
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, Romain Banchereau, Stefanie Morris, Leah Adler, Velimir Gayevskiy, Ahmed M Elhossiny, Minu K Srivastava, Namrata S Patil...> ;Cancer Cell. 2024 Mar 11
1 citations
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
Li, Z., Zhuang, X., Pan, C., Yan, Y., Thummalapalli, R., Hallin, J., Torborg, S., Singhal, A., Chang, J., Manchado, E., Dow, L., Yaeger, R., Christensen, J., Lowe, S.,...> ;Cancer Discovery. 2024 Feb 8
First-in-human imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.
Tendler, S., Dunphy, M., Agee, M., O'Donoghue, J., Aly, R., Choudhury, N., Kesner, A., Kirov, A., Mauguen, A., Baine, M., Schoder, H., Weber, W., Rekhtman, N., Lyashch...> ;Medrxiv. 2024 Jan 11
Role of CD38 in anti-tumor immunity of small cell lung cancer.
Hirokazu Taniguchi, Shweta S Chavan, Hiroshi Mukae, Triparna Sen, Andrew Chow, Joseph M Chan, Charles M Rudin> ;Frontiers in Immunology. 2024 Jan 1
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Nishino, M., Zhang, T., LoPiccolo, J., Paweletz, C., Gokhale, P., Ivanova, E., Saldanha, A., Lockwood, W., Somwar, R., Jänne, P., Odintsov, I., Makarem, M., Bachert, S...> ;Journal of Thoracic Oncology. 2023 Dec 26
3 citations
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consoli...
Tsai, C., Yang, J., Shaverdian, N., Patel, J., Shepherd, A., Eng, J., Guttmann, D., Yeh, R., Gelblum, D., Namakydoust, A., Preeshagul, I., Modi, S., Seidman, A., Train...> ;Lancet. 2024 Jan 13
2 citations
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Charles M Rudin, Stephen V Liu, Ross A Soo, Shun Lu, Min Hee Hong, Jong-Seok Lee, Maciej Bryl, Daphne W Dumoulin, Achim Rittmeyer, Chao-Hua Chiu, Ozgur Ozyilkan, Melis...> ;Journal of Clinical Oncology. 2024 Jan 20
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Hye Ryun Kim, Mark M Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet K Cheema, Delvys Rodriguez-Abreu, Mirjana Wollner, James Chih-Hsin ...> ;JTO Clinical and Research Reports. 2023 Nov 1
7 citations
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Anastasia-Maria Zavitsanou, Ray Pillai, Yuan Hao, Warren L Wu, Eric Bartnicki, Triantafyllia Karakousi, Sahith Rajalingam, Alberto Herrera, Angeliki Karatza, Ali Rashi...> ;Cell Reports. 2023 Nov 28
1 citations
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and...
Soo-Ryum Yang, Erika Gedvilaite, Ryan Ptashkin, Jason Chang, John Ziegler, Douglas A Mata, Liliana B Villafania, Khedoudja Nafa, Jaclyn F Hechtman, Ryma Benayed, Ahmet...> ;Journal of Thoracic Oncology. 2024 Mar 1
2 citations
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, Teng Fei, Hannah L Kalvin, Jacklynn V Egger, Hira Rizvi, Rohit Thummalapalli, Guiseppe Lamberti, Andrew Plodkowski, Ma...> ;The Oncologist. 2023 Nov 2
1 citations
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Ryan D Gentzler, Liza C Villaruz, John C Rhee, Bethany Horton, Joseph Mock, Michael Hanley, Kyeongmin Kim, Michelle A Rudek, Mitch A Phelps, Michael A Carducci, Richar...> ;The Oncologist. 2023 Nov 2
2 citations
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Alvaro Quintanal-Villalonga, Vidushi Durani, Amin Sabet, Esther Redin, Kenta Kawasaki, Moniquetta Shafer, Wouter R Karthaus, Samir Zaidi, Yingqian A Zhan, Parvathy Man...> ;Science Translational Medicine. 2023 Aug 2
3 citations
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V Alessi, Federica Pecci, Giuseppe Lamberti, Ale...> ;Clinical Cancer Research. 2023 Nov 1
1 citations
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
Arielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe L...> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
1 citations
De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways.
Subhamoy Chakraborty, Charles Coleman, Parvathy Manoj, Deniz Demircioglu, Nisargbhai Shah, Elisa de Stanchina, Charles M Rudin, Dan Hasson, Triparna Sen> ;Clinical Cancer Research. 2023 Sep 1
8 citations
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Charles M Rudin, Martin Reck, Melissa L Johnson, Fiona Blackhall, Christine L Hann, James Chih-Hsin Yang, Julie M Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Lu...> ;Journal of Hematology & Oncology. 2023 Jun 24
Breathing room - focusing on the 'other' lung cancer.
Charles M Rudin> ;Nature Cancer. 2023 Sep 1
11 citations
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
Charles M Rudin, David Balli, W Victoria Lai, Allison L Richards, Evelyn Nguyen, Jacklynn V Egger, Noura J Choudhury, Triparna Sen, Andrew Chow, John T Poirier, Willia...> ;Journal of Thoracic Oncology. 2023 Sep 1
1 citations
CRACD loss promotes small cell lung cancer tumorigenesis via EZH2-mediated immune evasion.
Shengzhe Zhang, Kee-Beom Kim, Yuanjian Huang, Dong-Wook Kim, Bongjun Kim, Kyung-Pil Ko, Gengyi Zou, Jie Zhang, Sohee Jun, Nicole A Kirk, Ye Eun Hwang, Young Ho Ban, Ch...> ;Biorxiv. 2023 May 17
Join now to see all

Journal Articles

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers
G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology

Other

Head and neck squamous cell carcinogenesis: Molecular and genetic alterations
Rudin CM, Marur S
http://www.uptodate.com/contents/head-and-neck-squamous-cell-carcinogenesis-molecular-and-genetic-al
UpToDate, Wolters Kluwer Health - 2012-04-09
Chemoprevention in oral dysplasia and head and neck cancer
Rudin CM, Marur S
http://www.uptodate.com/contents/chemoprevention-in-oral-dysplasia-and-head-and-neck-cancer
UpToDate, Wolters Kluwer Health - 2012-05-31

Press Mentions

MSK Research Highlights, November 23, 2022November 23rd, 2022
Scientists Unlock Potential for a Small Cell Lung Cancer Blood TestAugust 27th, 2022
Scientists Unlock Potential for a Small Cell Lung Cancer Blood TestAugust 24th, 2022
Join now to see all

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS North Carolina BlueOptions PPO
Blue Shield California PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment